The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer.
Breast cancer
ISG15
Interferon-stimulated gene 15
Prognosis
Progression
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
20
05
2020
accepted:
28
09
2020
pubmed:
20
10
2020
medline:
1
6
2021
entrez:
19
10
2020
Statut:
ppublish
Résumé
Lymphovascular invasion (LVI) is a prognostic factor in early-stage invasive breast cancer (BC). Through bioinformatics, data analyses of multiple BC cohorts revealed the positive association between interferon-stimulated gene 15 (ISG15) LVI status. Thus, we explored the prognostic significance of ISG15 in BC. The prognostic significance of ISG15 mRNA was assessed in METABRIC (n = 1980), TCGA (n = 854) and Kaplan-Meier Plotter (n = 3951). ISG15 protein was evaluated using immunohistochemistry (n = 859) in early-stage invasive BC patients with long-term follow-up. The associations between ISG15 expression and clinicopathological features, expression of immune cell markers and patient outcome data were evaluated. High mRNA and protein ISG15 expression were associated with LVI, higher histological grade, larger tumour size, hormonal receptor negativity, HER2 positivity, p53 and Ki67. High ISG15 protein expression was associated with HER2-enriched BC subtypes and immune markers (CD8, FOXP3 and CD68). High ISG15 mRNA and ISG15 expressions were associated with poor patient outcome. Cox proportional multivariate analysis revealed that the elevated ISG15 expression was an independent prognostic factor of shorter BC-specific survival. This study provides evidence for the role of ISG15 in LVI development and BC prognosis. Further functional studies in BC are warranted to evaluate the therapeutic potential of ISG15.
Sections du résumé
BACKGROUND
BACKGROUND
Lymphovascular invasion (LVI) is a prognostic factor in early-stage invasive breast cancer (BC). Through bioinformatics, data analyses of multiple BC cohorts revealed the positive association between interferon-stimulated gene 15 (ISG15) LVI status. Thus, we explored the prognostic significance of ISG15 in BC.
METHODS
METHODS
The prognostic significance of ISG15 mRNA was assessed in METABRIC (n = 1980), TCGA (n = 854) and Kaplan-Meier Plotter (n = 3951). ISG15 protein was evaluated using immunohistochemistry (n = 859) in early-stage invasive BC patients with long-term follow-up. The associations between ISG15 expression and clinicopathological features, expression of immune cell markers and patient outcome data were evaluated.
RESULTS
RESULTS
High mRNA and protein ISG15 expression were associated with LVI, higher histological grade, larger tumour size, hormonal receptor negativity, HER2 positivity, p53 and Ki67. High ISG15 protein expression was associated with HER2-enriched BC subtypes and immune markers (CD8, FOXP3 and CD68). High ISG15 mRNA and ISG15 expressions were associated with poor patient outcome. Cox proportional multivariate analysis revealed that the elevated ISG15 expression was an independent prognostic factor of shorter BC-specific survival.
CONCLUSION
CONCLUSIONS
This study provides evidence for the role of ISG15 in LVI development and BC prognosis. Further functional studies in BC are warranted to evaluate the therapeutic potential of ISG15.
Identifiants
pubmed: 33073304
doi: 10.1007/s10549-020-05955-1
pii: 10.1007/s10549-020-05955-1
pmc: PMC7867506
doi:
Substances chimiques
Biomarkers, Tumor
0
Cytokines
0
Ubiquitins
0
ISG15 protein, human
60267-61-0
Interferons
9008-11-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
293-305Références
Aleskandarany MA, Sonbul SN, Mukherjee A, Rakha EA (2015) Molecular mechanisms underlying lymphovascular invasion in invasive breast cancer. Pathobiology 82(3–4):113–123. https://doi.org/10.1159/000433583
doi: 10.1159/000433583
pubmed: 26330352
Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z, Macmillan D, Ellis IO (2012) The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer 118(15):3670–3680. https://doi.org/10.1002/cncr.26711
doi: 10.1002/cncr.26711
pubmed: 22180017
Zhang S, Zhang D, Yi S, Gong M, Lu C, Cai Y, Tang X, Zou L (2017) The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis. Oncotarget 8(2):2863–2873. https://doi.org/10.18632/oncotarget.13752
doi: 10.18632/oncotarget.13752
pubmed: 27926511
Liu YL, Saraf A, Lee SM, Zhong X, Hibshoosh H, Kalinsky K, Connolly EP (2016) Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat 157(3):555–564. https://doi.org/10.1007/s10549-016-3837-5
doi: 10.1007/s10549-016-3837-5
pubmed: 27225388
pmcid: 5337480
Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA (2019) A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. Br J Cancer 120(12):1129–1136. https://doi.org/10.1038/s41416-019-0486-6
doi: 10.1038/s41416-019-0486-6
pubmed: 31114020
pmcid: 6738092
Kadota K, Nakai Y, Shimizu K (2008) A weighted average difference method for detecting differentially expressed genes from microarray data. Algorithms Molecular Biol 3:8. https://doi.org/10.1186/1748-7188-3-8
doi: 10.1186/1748-7188-3-8
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550. https://doi.org/10.1073/pnas.0506580102
doi: 10.1073/pnas.0506580102
pubmed: 16199517
Hermann MR, Jakobson M, Colo GP, Rognoni E, Jakobson M, Kupatt C, Posern G, Fassler R (2016) Integrins synergise to induce expression of the MRTF-A-SRF target gene ISG15 for promoting cancer cell invasion. J Cell Sci 129(7):1391–1403. https://doi.org/10.1242/jcs.177592
doi: 10.1242/jcs.177592
pubmed: 26872785
Desai SD, Reed RE, Burks J, Wood LM, Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S, Sankar S (2012) ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood, NJ) 237(1):38–49. https://doi.org/10.1258/ebm.2011.011236
doi: 10.1258/ebm.2011.011236
Okumura F, Okumura AJ, Uematsu K, Hatakeyama S, Zhang DE, Kamura T (2013) Activation of double-stranded RNA-activated protein kinase (PKR) by interferon-stimulated gene 15 (ISG15) modification down-regulates protein translation. J Biol Chem 288(4):2839–2847. https://doi.org/10.1074/jbc.M112.401851
doi: 10.1074/jbc.M112.401851
pubmed: 23229543
Okumura F, Zou W, Zhang DE (2007) ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev 21(3):255–260. https://doi.org/10.1101/gad.1521607
doi: 10.1101/gad.1521607
pubmed: 17289916
pmcid: 1785121
D’Cunha J, Knight E Jr, Haas AL, Truitt RL, Borden EC (1996) Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA 93(1):211–215. https://doi.org/10.1073/pnas.93.1.211
doi: 10.1073/pnas.93.1.211
pubmed: 8552607
Bogunovic D, Boisson-Dupuis S, Casanova JL (2013) ISG15: leading a double life as a secreted molecule. Exp Mol Med 45:e18. https://doi.org/10.1038/emm.2013.36
doi: 10.1038/emm.2013.36
pubmed: 23579383
pmcid: 3641400
Villarreal DO, Wise MC, Siefert RJ, Yan J, Wood LM, Weiner DB (2015) Ubiquitin-like molecule ISG15 acts as an immune adjuvant to enhance antigen-specific CD8 T-cell tumor immunity. Mol Ther 23(10):1653–1662. https://doi.org/10.1038/mt.2015.120
doi: 10.1038/mt.2015.120
pubmed: 26122932
pmcid: 4817913
Yeung TL, Tsai CC, Leung CS, Au Yeung CL, Thompson MS, Lu KH, Freedman RS, Birrer MJ, Wong KK, Mok SC (2018) ISG15 promotes ERK1 ISGylation, CD8+ T cell activation and suppresses ovarian cancer progression. Cancers. https://doi.org/10.3390/cancers10120464
doi: 10.3390/cancers10120464
pubmed: 30469497
pmcid: 6316352
Fan JB, Miyauchi-Ishida S, Arimoto K, Liu D, Yan M, Liu CW, Gyorffy B, Zhang DE (2015) Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation. Proc Natl Acad Sci USA 112(46):14313–14318. https://doi.org/10.1073/pnas.1505690112
doi: 10.1073/pnas.1505690112
pubmed: 26515094
Chen YL, Wu WL, Jang CW, Yen YC, Wang SH, Tsai FY, Shen YY, Chen YW (2019) Interferon-stimulated gene 15 modulates cell migration by interacting with Rac1 and contributes to lymph node metastasis of oral squamous cell carcinoma cells. Oncogene 38(23):4480–4495. https://doi.org/10.1038/s41388-019-0731-8
doi: 10.1038/s41388-019-0731-8
pubmed: 30765861
Zuo C, Sheng X, Ma M, Xia M, Ouyang L (2016) ISG15 in the tumorigenesis and treatment of cancer: an emerging role in malignancies of the digestive system. Oncotarget 7(45):74393–74409. https://doi.org/10.18632/oncotarget.11911
doi: 10.18632/oncotarget.11911
pubmed: 27626310
pmcid: 5342061
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352. https://doi.org/10.1038/nature10983
doi: 10.1038/nature10983
pubmed: 22522925
pmcid: 3440846
Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Perou CM (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163(2):506–519. https://doi.org/10.1016/j.cell.2015.09.033
doi: 10.1016/j.cell.2015.09.033
pubmed: 26451490
pmcid: 4603750
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401–404. https://doi.org/10.1158/2159-8290.cd-12-0095
doi: 10.1158/2159-8290.cd-12-0095
pubmed: 22588877
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1. https://doi.org/10.1126/scisignal.2004088
doi: 10.1126/scisignal.2004088
pubmed: 23550210
pmcid: 4160307
Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123(3):725–731. https://doi.org/10.1007/s10549-009-0674-9
doi: 10.1007/s10549-009-0674-9
pubmed: 20020197
Kariri YA, Joseph C, Kurozumi S, Toss MS, Alsaleem M, Raafat S, Mongan NP, Aleskandarany MA, Green AR, Rakha EA (2019) Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-019-05466-8
doi: 10.1007/s10549-019-05466-8
pubmed: 31679074
pmcid: 6987050
Rakha EA, Agarwal D, Green AR, Ashankyty I, Ellis IO, Ball G, Alaskandarany MA (2017) Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. Histopathology 70(4):622–631. https://doi.org/10.1111/his.13108
doi: 10.1111/his.13108
pubmed: 27782306
Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO (2015) Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol 68(2):93–99. https://doi.org/10.1136/jclinpath-2014-202571
doi: 10.1136/jclinpath-2014-202571
pubmed: 25488926
Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S, Ellis IO, Rakha EA (2016) MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cancer 114(8):917–928. https://doi.org/10.1038/bjc.2016.46
doi: 10.1038/bjc.2016.46
pubmed: 26954716
pmcid: 4984797
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American society of clinical oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134(6):907–922. https://doi.org/10.1043/1543-2165-134.6.907
doi: 10.1043/1543-2165-134.6.907
pubmed: 20524868
pmcid: 3073033
Muftah AA, Aleskandarany MA, Al-Kaabi MM, Sonbul SN, Diez-Rodriguez M, Nolan CC, Caldas C, Ellis IO, Rakha EA, Green AR (2017) Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast Cancer Res Treat 164(2):341–348. https://doi.org/10.1007/s10549-017-4270-0
doi: 10.1007/s10549-017-4270-0
pubmed: 28478613
pmcid: 5487701
Rolland P, Spendlove I, Madjd Z, Rakha EA, Patel P, Ellis IO, Durrant L (2007) The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer 120(6):1311–1317. https://doi.org/10.1002/ijc.22430
doi: 10.1002/ijc.22430
pubmed: 17187363
Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO (2005) E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 46(6):685–693. https://doi.org/10.1111/j.1365-2559.2005.02156.x
doi: 10.1111/j.1365-2559.2005.02156.x
pubmed: 15910600
Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M, Ellis IO (2012) A CD44
doi: 10.1007/s10549-011-1865-8
pubmed: 22119938
Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PD, Caldas C (2014) Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 25(8):1536–1543. https://doi.org/10.1093/annonc/mdu191
doi: 10.1093/annonc/mdu191
pubmed: 24915873
Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2012) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65(2):159–163. https://doi.org/10.1136/jclinpath-2011-200355
doi: 10.1136/jclinpath-2011-200355
pubmed: 22049225
Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7(5):e1000279. https://doi.org/10.1371/journal.pmed.1000279
doi: 10.1371/journal.pmed.1000279
pubmed: 20520800
pmcid: 2876119
Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350. https://doi.org/10.1002/ijc.21004
doi: 10.1002/ijc.21004
pubmed: 15818618
McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Archiv Pathol Lab Med 109(8):716–721
Alsaleem M, Toss MS, Joseph C, Aleskandarany M, Kurozumi S, Alshankyty I, Ogden A, Rida PCG, Ellis IO, Aneja R, Green AR, Mongan NP, Rakha EA (2019) The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts. Mod Pathol 32(7):967–976. https://doi.org/10.1038/s41379-019-0209-9
doi: 10.1038/s41379-019-0209-9
pubmed: 30760857
Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG (2018) Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst 110(8):803–811. https://doi.org/10.1093/jnci/djy088
doi: 10.1093/jnci/djy088
pubmed: 29873743
pmcid: 6093349
Lohse M, Bolger AM, Nagel A, Fernie AR, Lunn JE, Stitt M, Usadel B (2012) RobiNA: a user-friendly, integrated software solution for RNA-Seq-based transcriptomics. Nucleic Acids Res 40(1):W622-627. https://doi.org/10.1093/nar/gks540
doi: 10.1093/nar/gks540
pubmed: 22684630
pmcid: 3394330
Oliveros JC (2020) Venn diagrams for comparing lists. https://bioinfogp.cnb.csic.es/tools/venny_old/venny.php .
Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z (2009) GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinform 10:48. https://doi.org/10.1186/1471-2105-10-48
doi: 10.1186/1471-2105-10-48
Cruz-Ramos E, Macias-Silva M, Sandoval-Hernandez A, Tecalco-Cruz AC (2019) Non-muscle myosin IIA is post-translationally modified by interferon-stimulated gene 15 in breast cancer cells. Int J Biochem Cell Biol 107:14–26. https://doi.org/10.1016/j.biocel.2018.12.002
doi: 10.1016/j.biocel.2018.12.002
pubmed: 30529400
Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y (2012) The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother 61(5):689–700. https://doi.org/10.1007/s00262-011-1129-9
doi: 10.1007/s00262-011-1129-9
pubmed: 22057675
Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB, Hassel BA, Dragnev K, Dmitrovsky E (2008) UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther 7(12):3780–3788. https://doi.org/10.1158/1535-7163.mct-08-0753
doi: 10.1158/1535-7163.mct-08-0753
pubmed: 19074853
pmcid: 2638083
Satake H, Tamura K, Furihata M, Anchi T, Sakoda H, Kawada C, Iiyama T, Ashida S, Shuin T (2010) The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer. Oncol Rep 23(1):11–16
pubmed: 19956859
Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF (2006) Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer 94(10):1465–1471. https://doi.org/10.1038/sj.bjc.6603099
doi: 10.1038/sj.bjc.6603099
pubmed: 16641915
pmcid: 2361278
Baldi P, Long AD (2001) A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. Bioinformatics (Oxford, England) 17(6):509–519. https://doi.org/10.1093/bioinformatics/17.6.509
doi: 10.1093/bioinformatics/17.6.509
Liu Y, Beyer A, Aebersold R (2016) On the dependency of cellular protein levels on mRNA abundance. Cell 165(3):535–550. https://doi.org/10.1016/j.cell.2016.03.014
doi: 10.1016/j.cell.2016.03.014
pubmed: 27104977
Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20(1):119–131. https://doi.org/10.1016/j.ccr.2011.05.026
doi: 10.1016/j.ccr.2011.05.026
pubmed: 21741601
pmcid: 3180861
Meisel JL, Venur VA, Gnant M, Carey L (2018) Evolution of targeted therapy in breast cancer: where precision medicine began. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 38:78–86. https://doi.org/10.1200/edbk_201037
doi: 10.1200/edbk_201037
Banin-Hirata BK, de Oliveira CEC, Losi-Guembarovski R, Ozawa PMM, Vitiello GAF, de Almeida FC, Derossi DR, Andre ND, Watanabe MAE (2018) The prognostic value of regulatory T cells infiltration in HER2-enriched breast cancer microenvironment. Int Rev Immunol 37(3):144–150. https://doi.org/10.1080/08830185.2017.1401620
doi: 10.1080/08830185.2017.1401620
pubmed: 29257906
Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1):52–67. https://doi.org/10.1016/j.cell.2010.03.015
doi: 10.1016/j.cell.2010.03.015
pubmed: 20371345
pmcid: 2862057
Li Y, Bai W, Zhang L (2018) The overexpression of CD80 and ISG15 are associated with the progression and metastasis of breast cancer by a meta-analysis integrating three microarray datasets. Pathol Oncol Res. https://doi.org/10.1007/s12253-018-0478-5
doi: 10.1007/s12253-018-0478-5
pubmed: 30523602
pmcid: 7109161
Huang YF, Bulavin DV (2014) Oncogene-mediated regulation of p53 ISGylation and functions. Oncotarget 5(14):5808–5818. https://doi.org/10.18632/oncotarget.2199
doi: 10.18632/oncotarget.2199
pubmed: 25071020
pmcid: 4170631
Bui T, Schade B, Cardiff RD, Aina OH, Sanguin-Gendreau V, Muller WJ (2017) Beta-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model. Proc Natl Acad Sci USA 114(5):E707–E716. https://doi.org/10.1073/pnas.1610383114
doi: 10.1073/pnas.1610383114
pubmed: 28096336
Rezaei M, Friedrich K, Wielockx B, Kuzmanov A, Kettelhake A, Labelle M, Schnittler H, Baretton G, Breier G (2012) Interplay between neural-cadherin and vascular endothelial-cadherin in breast cancer progression. Breast Cancer Res 14(6):R154. https://doi.org/10.1186/bcr3367
doi: 10.1186/bcr3367
pubmed: 23216791
pmcid: 4053141
Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT (2012) Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136(2):331–345. https://doi.org/10.1007/s10549-012-2289-9
doi: 10.1007/s10549-012-2289-9
pubmed: 23073759
Guan X (2015) Cancer metastases: challenges and opportunities. Acta Pharm Sin B 5(5):402–418. https://doi.org/10.1016/j.apsb.2015.07.005
doi: 10.1016/j.apsb.2015.07.005
pubmed: 26579471
pmcid: 4629446
Shankar J, Nabi IR (2015) Correction: actin cytoskeleton regulation of epithelial mesenchymal transition in metastatic cancer cells. PLoS ONE 10(7):e0132759. https://doi.org/10.1371/journal.pone.0132759
doi: 10.1371/journal.pone.0132759
pubmed: 26167914
pmcid: 4500445
Fife CM, McCarroll JA, Kavallaris M (2014) Movers and shakers: cell cytoskeleton in cancer metastasis. Br J Pharmacol 171(24):5507–5523. https://doi.org/10.1111/bph.12704
doi: 10.1111/bph.12704
pubmed: 24665826
pmcid: 4290699
Nersesian S, Williams R, Newsted D, Shah K, Young S, Evans PA, Allingham JS, Craig AW (2018) Effects of modulating actin dynamics on HER2 cancer cell motility and metastasis. Sci Rep 8(1):17243. https://doi.org/10.1038/s41598-018-35284-9
doi: 10.1038/s41598-018-35284-9
pubmed: 30467396
pmcid: 6250728